Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies.
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
12
02
2021
received:
05
01
2021
accepted:
24
02
2021
pubmed:
2
3
2021
medline:
18
9
2021
entrez:
1
3
2021
Statut:
ppublish
Résumé
The treatment of gout with allopurinol is effective at reducing urate levels and the frequency of flares. Several observational studies have shown important reductions in mortality with allopurinol use, with wide variations in results. We undertook this review to assess the extent of bias in these studies, particularly time-related biases such as immortal time bias. We searched the literature to identify all observational studies describing the effect of allopurinol use versus nonuse on all-cause mortality. We identified 12 observational studies, of which 3 were affected by immortal time bias and 3 by immeasurable time bias, while the remaining 6 studies avoided these time-related biases. Reductions in all-cause mortality with allopurinol use were observed among the studies with immortal time bias, with a pooled hazard ratio (HR) of death associated with allopurinol of 0.71 (95% confidence interval [95% CI] 0.50-1.01), as well as in those with immeasurable time bias (pooled HR 0.62 [95% CI 0.56-0.67]). The 6 studies that avoided these biases demonstrated a null effect of allopurinol on mortality (pooled HR 0.99 [95% CI 0.87-1.11]), though the lack of an analysis based on treatment adherence may have attenuated the effect. Observational studies are important to provide real-world data on medication effects. The observational studies showing significantly decreased mortality with allopurinol treatment cannot be used as evidence, however, mainly due to time-related biases that tend to greatly exaggerate the potential benefit of treatments. The ALL-HEART randomized trial, which is currently underway and evaluates the effect of adding allopurinol to usual care (compared to no added treatment), will provide reliable evidence on mortality.
Substances chimiques
Gout Suppressants
0
Uric Acid
268B43MJ25
Allopurinol
63CZ7GJN5I
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1749-1757Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021, American College of Rheumatology.
Références
Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2015;22:335-43.
Gupta MK, Singh JA. Cardiovascular disease in gout and the protective effect of treatments including urate-lowering therapy [review]. Drugs 2019;79:531-41.
Fisher MC, Rai SK, Lu N, Zhang Y, Choi HK. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis 2017;76:1289-94.
Mitchell S, Liedgens H, Johannes E. THU0462 Mortality in patients with gout: a systematic review [poster]. Ann Rheum Dis 2017;76:382.
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol 2020;72:879-95.
Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d'Avila R, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2018;18:24.
Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open 2016;6:e013774.
Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol 2015;42:1694-701.
Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 2009;63:1327-33.
Hay CA, Prior JA, Belcher J, Mallen CD, Roddy E. Mortality in patients with gout treated with allopurinol: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2020 doi: https://onlinelibrary.wiley.com/doi/10.1002/acr.24205. E-pub ahead of print.
Suissa S, Dell'Aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2020;29:1101-10.
Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008;167:492-9.
Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008;168:329-35.
Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-34.
Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 2012;18:694-701.
Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007;16:241-9.
Clarson LE, Hider SL, Belcher J, Roddy E, Mallen CD. Factors influencing allopurinol initiation in primary care. Ann Fam Med 2017;15:557-60.
Suissa S, Moodie EE, Dell'Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf 2017;26:459-68.
Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:1358-64.
Larsen KS, Pottegård A, Lindegaard HM, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med 2016;129:299-306.
Weisman A, Tomlinson GA, Lipscombe LL, Perkins BA, Hawker GA. Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: a retrospective, population-based cohort study. Diabetes Obes Metab 2019;21:1322-9.
Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009;48:804-6.
Tsuruta Y, Nitta K, Akizawa T, Fukuhara S, Saito A, Karaboyas A, et al. Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS. Int Urol Nephrol 2014;46:1833-41.
Dubreuil M, Zhu Y, Zhang Y, Seeger JD, Lu N, Rho YH, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2015;74:1368-72.
Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis. Rheumatology (Oxford) 2015;54:2145-50.
Ju C, Lai RW, Li KH, Hung JK, Lai JC, Ho J, et al. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology (Oxford) 2020;59:2340-9.
Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford) 2013;52:1126-31.
Singh JA, Richman J, Yang S, Bridges SL, Saag K. Allopurinol adherence and its predictors in gout: a national cohort study in US veterans. Lancet Rheumatol 2020;2:e281-91.
Scheepers L, van Onna M, Stehouwer CD, Singh JA, Arts IC, Boonen A. Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum 2018;47:689-702.
Scheepers L, Burden AM, Arts IC, Spaetgens B, Souverein P, de Vries F, et al. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology (Oxford) 2018;57:1641-50.
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence-what is it and what can it tell us? N Engl J Med 2016;375:2293-7.
Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005;330:1059-63.
Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005;165:62-7.
Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164:1427-36.
Abrahami D, Hudson M, Suissa S. Statins and lower mortality in rheumatic diseases: an effect of immortal time bias? Semin Arthritis Rheum 2021;51:211-8.
Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 2016;79:70-5.